Get the Stockscreener App
51.20
1.10%
0.6136
Amphastar Pharmaceuticals Inc stock is traded at $51.20, with a volume of 85,006.
It is up +1.10% in the last 24 hours and up +9.47% over the past month.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$50.59
Open:
$50.59
24h Volume:
85,006
Relative Volume:
0.26
Market Cap:
$2.51B
Revenue:
$712.89M
Net Income/Loss:
$166.52M
P/E Ratio:
26.26
EPS:
1.95
Net Cash Flow:
$178.13M
1W Performance:
-0.01%
1M Performance:
+9.47%
6M Performance:
+20.45%
1Y Performance:
+9.78%
1-Day Range:
$50.33
$51.23
1-Week Range:
$50.04
$51.57
52-Week Range:
$36.56
$65.92
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Report Pre - GuruFocus.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Lowered to “Hold” at StockNews.com - Defense World
Amphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded to Hold Rating by StockNews.com - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Raymond James & Associates - Defense World
Allspring Global Investments Holdings LLC Trims Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
International Assets Investment Management LLC Buys Shares of 22,809 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Trend Tracker for (AMPH) - Stock Traders Daily
Amphastar Pharmaceuticals (AMPH) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024 - AccessWire
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Boston Trust Walden Corp Purchases Shares of 539,639 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? - Yahoo Finance
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade) (AMPH) - Seeking Alpha
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Moody Aldrich Partners LLC - MarketBeat
Possible Bearish Signals With Amphastar Pharmaceuticals Insiders Disposing Stock - Simply Wall St
nVerses Capital LLC Buys 400 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report? - MSN
(AMPH) Investment Report - Stock Traders Daily
GAMMA Investing LLC Increases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to Buy by StockNews.com - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by StockNews.com to “Buy” - Defense World
Amphastar Pharm Shows Rising Relative Strength; Still Shy Of Key Benchmark - MSN
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Is Going Strong: Is the Market Following Fundamentals? - Yahoo Finance
Short Interest in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Rises By 5.3% - MarketBeat
Truist Financial Corp Trims Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade - MSN
Epinephrine Injection Market 2034 | Key Brands -Mylan Inc, Impax, ALK Abello, Lincoln Medical Ltd, Pfizer, Amphastar, Em – IndiaPolitics.com - IndiaPolitics.com
The Manufacturers Life Insurance Company Purchases 954 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Lowered to Hold at StockNews.com - Defense World
Is Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) The Top Stock With Improving Technical Ratings According To Piper Sandler? - Insider Monkey
StockNews.com Lowers Amphastar Pharmaceuticals (NASDAQ:AMPH) to Hold - MarketBeat
SG Americas Securities LLC Makes New Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
When the Price of (AMPH) Talks, People Listen - Stock Traders Daily
Sei Investments Co. Sells 4,087 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Hsbc Holdings PLC Sells 711 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals' (NASDAQ:AMPH) underlying earnings growth outpaced the solid return generated for shareholders over the past three years - Simply Wall St
Implied Volatility Surging for Amphastar Pharmaceuticals (AMPH) Stock Options - MSN
Point72 DIFC Ltd Sells 8,406 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Millennium Management LLC Buys 338,653 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Millennium Management LLC Boosts Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
ProShare Advisors LLC Sells 2,133 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Down 3.6% - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stake Boosted by Squarepoint Ops LLC - Defense World
Point72 Asia Singapore Pte. Ltd. Sells 3,756 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Dimensional Fund Advisors LP - Defense World
Point72 Asset Management L.P. Lowers Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Aurora Investment Counsel Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Dimensional Fund Advisors LP Reduces Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Marshall Wace LLP Buys Shares of 227,127 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amphastar Pharmaceuticals Inc Stock (AMPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Sep 13 '24 |
Sale |
48.26 |
3,000 |
144,784 |
118,388 |
| Zhang Jack Y. | CEO & CHIEF SCIENTIFIC OFFICER |
Sep 13 '24 |
Option Exercise |
14.69 |
100,000 |
1,469,000 |
2,633,554 |
| Petersen Floyd F. | Director |
Sep 05 '24 |
Sale |
46.47 |
3,000 |
139,417 |
75,409 |
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):